Kendall Morrison, PhD, TAE Life Sciences, Santa Monica, CA, comments on the development of antibody boron conjugates (ABCs) to treat glioblastoma with boron neutron capture therapy (BNCT). Unlike existing boron compounds including boronophenylalanine (BPA), ABCs are actively internalized by the target cells and can deliver more boron compared to small molecule drugs. Whilst delivery of ABCs remain a challenge due to the blood-brain barrier, they may be a promising therapy in patients with EFGR-mutant brain tumors. This interview took place at the British Neuro-Oncology Society (BNOS) Annual Meeting 2022.